STING1 and neoplasm: In particular, systemic administration of STING agonists may systemically activate STING, thereby inducing excessive pro-inflammatory factors to be secreted by both tumor and non-tumor tissues, and even triggering an immune storm [63,68], which has adverse effects on normal tissues and cells.